Skip to content
Home/Companies/Pharma/Catalent

Catalent

Pharma·US·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Catalent?

Catalent is currently owned by Novo Holdings through Novo Holdings Principal Investments (1999 vintage), since 2024.

Hand-verified · updated 2026-08-18

Novo Holdings
Investor
Novo Holdings
Novo Holdings Principal Investments · 1999 · Buyout

Key facts

HQUnited States
SectorPharma
StatusActive

More from Novo Holdings Principal Investments

Other portfolio companies in the same fund.

Tempus AI
Active
HealthTechUS· 2026
Benchmark Genetics
Active
AgTechUK· 2025
KalVista Pharmaceuticals
Active
PharmaUS· 2025
Schott Poonawalla
Active
IndustrialsIndia· 2025
Inozyme Pharma
Exited 2025
BiotechUS· 2023
to
Manipal Hospitals
Active
HealthcareIndia· 2023

More PE-backed in Pharma

Comparable pharma deals from other GPs.

CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
iNova
iNova
Exited 2021
The Carlyle GroupAustralia
to
Jubilant Life Sciences
Active
General AtlanticIndia
Laboratoires Delbert
Active
SocadifFrance
Track Catalent

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Catalent?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Catalent.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue